Effect of trimetazidine on left ventricular ejection fraction and time to develop 1mm ST depression in patients with chronic stable Angina: A meta-analysis Alvin V. Amoguis
Subject(s): Abstract: Search Strategies: A systematic search was performed with the use of electronic database, including Medline PubMed, Ovid, the Cochrane Library. Selection Criteria: A study was included in this meta-analysis if it was published, randomised, placebo-controlled and it reported the effect of trmetazidine with placebo on stable angina pectoris and /or myocardial ischemia. Data collection and analysis: Details of the study design, patient characteristics, intervention, duration of therapy were extracted by the author. Analysis was done with the calculation of the weighted mean difference and chi-square test using standard meta-analysis software (RevMan 4,2,3) . Main Results: The result of our meta-analysis showed that compared to placebo, trimetazidine significantly increases ejection fraction and time to develop 1 mm ST depression during exercise. Overall,the improvement of ejection fraction was 14.67% (CI 12.59 - 16.75). The study was relatively heterogeneous in our analysis by chi-square test. This is due to various in parameters in the included studies as previously mentioned. Reviewers conclusion: The result of this meta-analysis suggest that trimetazidine is superior to placebo in increasing the ejection fraction and time to developing 1mm ST depression in patients with chronic stable angina. However, the overall quality of the included studies weakens the validity of these findings. Except for influenza-like symptoms, there are no studies demonstrating detrimental effects of trimetazidine intake. Therefore, with its other cardiovascular benefits, trimetazidine is good alternatiove to treating patients with chronic stable angina.| Cover image | Item type | Current library | Home library | Collection | Shelving location | Call number | Materials specified | Vol info | URL | Copy number | Status | Notes | Date due | Barcode | Item holds | Item hold queue priority | Course reserves | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Journal Article
|
DOH Central Library Electronic Resource Section | J000430 (Browse shelf(Opens below)) | Available | D0001J000430 |
Search Strategies: A systematic search was performed with the use of electronic database, including Medline PubMed, Ovid, the Cochrane Library.
Selection Criteria: A study was included in this meta-analysis if it was published, randomised, placebo-controlled and it reported the effect of trmetazidine with placebo on stable angina pectoris and /or myocardial ischemia.
Data collection and analysis: Details of the study design, patient characteristics, intervention, duration of therapy were extracted by the author. Analysis was done with the calculation of the weighted mean difference and chi-square test using standard meta-analysis software (RevMan 4,2,3) .
Main Results: The result of our meta-analysis showed that compared to placebo, trimetazidine significantly increases ejection fraction and time to develop 1 mm ST depression during exercise. Overall,the improvement of ejection fraction was 14.67% (CI 12.59 - 16.75). The study was relatively heterogeneous in our analysis by chi-square test. This is due to various in parameters in the included studies as previously mentioned.
Reviewers conclusion: The result of this meta-analysis suggest that trimetazidine is superior to placebo in increasing the ejection fraction and time to developing 1mm ST depression in patients with chronic stable angina. However, the overall quality of the included studies weakens the validity of these findings. Except for influenza-like symptoms, there are no studies demonstrating detrimental effects of trimetazidine intake. Therefore, with its other cardiovascular benefits, trimetazidine is good alternatiove to treating patients with chronic stable angina.
The Filipino Family Physician, 2008 46 (2) pages 78-86
There are no comments on this title.